Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials

BACKGROUND AND PURPOSE: The efficacy of galcanezumab, a monoclonal antibody for migraine prevention, has been demonstrated in two pivotal trials in patients with episodic migraine. METHODS: EVOLVE‐1 and EVOLVE‐2 were identical phase 3, randomized, double‐blind, placebo‐controlled studies in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruff, D. D., Ford, J. H., Tockhorn‐Heidenreich, A., Stauffer, V. L., Govindan, S., Aurora, S. K., Terwindt, G. M., Goadsby, P. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155018/
https://www.ncbi.nlm.nih.gov/pubmed/31692188
http://dx.doi.org/10.1111/ene.14114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155018/
https://www.ncbi.nlm.nih.gov/pubmed/31692188
http://dx.doi.org/10.1111/ene.14114

Ejemplares similares